Insulet Executive and Leadership Team

Ashley McEvoy, the Director, President & Chief Executive Officer at Insulet, directs the overarching corporate strategy and long-term vision for the medical device manufacturer. Overseeing global operations, the Director, President & Chief Executive Officer ensures the Omnipod platform maintains market leadership while driving expansion into new therapeutic areas. This leadership role involves constant collaboration with the Board to align product innovation with patient needs. By prioritizing scalable manufacturing and clinical excellence, Ashley McEvoy directly impacts the company's ability to improve lives for individuals managing diabetes. Through rigorous oversight of organizational performance, McEvoy secures sustainable growth and operational efficiency across all international markets. The Director, President & Chief Executive Officer maintains a focus on delivering value to shareholders while advancing the core mission of simplifying insulin delivery through wearable technology.

Carsten Boess, the Chief Financial Officer at Insulet, manages the fiscal health and capital allocation strategies for the organization. Overseeing financial planning and analysis, the Chief Financial Officer ensures robust reporting standards and transparency for investors. This leadership role involves optimizing the balance sheet to support research and development initiatives for the Omnipod system. By monitoring global market trends, Carsten Boess identifies opportunities for cost-effective scaling of manufacturing processes. Boess maintains strict control over budgetary frameworks to ensure resources align with the strategic goals of the company. The Chief Financial Officer drives financial discipline across all departments, facilitating the expansion of subcutaneous drug delivery platforms. Through precise risk management and capital deployment, Boess supports the long-term financial stability required to maintain the competitive edge of the company in the medical device sector.

Timothy Stonesifer, the Chief Financial Officer, At Alcon Inc at Insulet, directs specialized financial operations and external reporting functions. Overseeing complex fiscal structures, the Chief Financial Officer, At Alcon Inc ensures compliance with international regulatory requirements for medical device manufacturers. This leadership role involves analyzing market data to forecast revenue streams from the Omnipod product line. By implementing advanced financial modeling, Timothy Stonesifer optimizes resource distribution to support the development of non-insulin subcutaneous drug delivery solutions. Stonesifer coordinates with internal audit teams to maintain high standards of corporate governance. The Chief Financial Officer, At Alcon Inc drives efficiency in supply chain financing, ensuring the company remains agile in a competitive global landscape. Through strategic financial oversight, Stonesifer contributes to the overall growth trajectory and market penetration of the company across diverse therapeutic areas.

Ana Chadwick, the Executive Vice President & Chief Financial Officer & Treasurer at Insulet, directs the treasury functions and global financial strategy. Overseeing liquidity management, the Executive Vice President & Chief Financial Officer & Treasurer ensures the company maintains the capital reserves necessary for large-scale manufacturing and R&D. This leadership role involves managing investor relations and communicating the financial health of the organization to the market. By optimizing tax structures and cash flow, Ana Chadwick supports the aggressive growth of the Omnipod platform. Chadwick coordinates with the Board to evaluate potential acquisitions and strategic partnerships that align with the long-term goals of the company. The Executive Vice President & Chief Financial Officer & Treasurer drives financial accountability across all business units. Through rigorous oversight of treasury operations, Chadwick secures the financial foundation required for the company to innovate in the medical device space.

Jane Hoffman, the Corporate Affairs Chief of Staff at Insulet, manages internal communications and strategic alignment across the executive leadership team. Overseeing corporate messaging, the Corporate Affairs Chief of Staff ensures consistent representation of the company mission to stakeholders and the public. This leadership role involves facilitating cross-functional projects that integrate medical device innovation with patient advocacy efforts. By streamlining communication channels, Jane Hoffman enhances the operational synergy between the executive office and regional teams. Hoffman coordinates high-level initiatives that support the expansion of the Omnipod platform into new geographic markets. The Corporate Affairs Chief of Staff drives engagement strategies that reinforce the reputation of the company as a leader in diabetes care. Through meticulous planning and execution, Hoffman ensures the organization remains focused on its core objective of improving patient outcomes through wearable technology.

Rakesh Pant, the Staff Software Engineer & Chief Technology Officer, Cloud Data Products at Insulet, architects the digital infrastructure and cloud-based data solutions for the Omnipod system. Overseeing software development, the Staff Software Engineer & Chief Technology Officer, Cloud Data Products ensures the seamless integration of wearable device data with patient management platforms. This leadership role involves designing secure, scalable architectures that support real-time insulin delivery monitoring. By leveraging advanced data analytics, Rakesh Pant drives the evolution of the digital ecosystem to improve user experience and clinical outcomes. Pant collaborates with engineering teams to implement robust cybersecurity protocols for all connected medical devices. The Staff Software Engineer & Chief Technology Officer, Cloud Data Products maintains a focus on technological innovation to keep the company at the forefront of the digital health industry. Through technical leadership, Pant enables the expansion of data-driven therapeutic solutions.

Hyunju Hwang, the Head Strategy & Operations Chief of Staff & Chief Technology Officer, Leadership Team at Insulet, directs the operational roadmap and technological integration for the company. Overseeing strategic planning, the Head Strategy & Operations Chief of Staff & Chief Technology Officer, Leadership Team ensures that technical development cycles align with market demand for the Omnipod system. This leadership role involves streamlining internal processes to accelerate the delivery of new subcutaneous drug platforms. By analyzing operational performance, Hyunju Hwang identifies bottlenecks and implements solutions to enhance manufacturing efficiency. Hwang coordinates with the executive team to prioritize technology investments that drive long-term value. The Head Strategy & Operations Chief of Staff & Chief Technology Officer, Leadership Team maintains a focus on operational excellence to support the global expansion of the company. Through strategic oversight, Hwang ensures the organization remains agile and responsive to the evolving needs of the medical device market.

Trang Ly, the Senior Vice President, Chief Medical Officer at Insulet, directs the clinical research and medical strategy for the Omnipod platform. Overseeing clinical trials, the Senior Vice President, Chief Medical Officer ensures that all product developments meet rigorous safety and efficacy standards. This leadership role involves collaborating with healthcare providers to understand the clinical requirements for insulin delivery and other subcutaneous drug therapies. By interpreting medical data, Trang Ly guides the development of features that improve patient adherence and health outcomes. Ly maintains relationships with regulatory bodies to facilitate the approval of new medical device applications. The Senior Vice President, Chief Medical Officer drives the scientific integrity of the company, ensuring that all innovations are grounded in clinical evidence. Through medical leadership, Ly supports the expansion of the company into new therapeutic areas, ultimately improving the quality of life for patients managing chronic conditions.